With three swings of the bat and one incredible night on the mound, Shohei Ohtani had what many -- including me -- argued is the greatest game in MLB history. We're all in awe of what the Los Angeles ...

EMERYVILLE, Calif., Oct. 21, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, ...

The Andhra Pradesh State Council of Higher Education (APSCHE) has announced the AP Law Common Entrance Test (LAWCET) phase 1 seat allotment result today, October 25, 2025. Candidates who filled in ...

Dubai, UAE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) continues to gain traction across the crypto market as it reaches another major milestone in its journey toward becoming one of the ...

– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses in CRC, PDAC, and endometrial ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year, before it entered the second part of a phase 1/2 lymphoma study. The dual-targeting CAR-T, dubbed bbT369, was being ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...

Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this year. Chugai revealed (PDF) the suspension of in-house development of the ...

91.5% of patients experienced a reduction in tumors and a disease control rate of 96.7%; nearly half the patients evaluated remain on treatment Low discontinuation rate due to adverse events of 4% ...

In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with ...